Loading stock data…
$3.43
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
CAMP in the Healthcare sector is trading at $3.43 with a market capitalization of $267M. Wall Street consensus targets $10.57 (7 analysts), implying a +208.2% move over the next 12 months. The stock is currently near its 52-week low of $2.86, remaining 21.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.78M↑ | $1.29M↑ | $348,000↓ | $795,000↓ | $1.50M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.38M↓ | -$13.07M↓ | -$12.78M↑ | -$13.16M↓ | -$13.03M |
| Net Income | -$33.53M↓ | -$18.33M↑ | -$40.28M↓ | -$15.10M↓ | -$12.59M |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the trea...